Karagiannis Tom C, El-Osta Assam
Molecular Radiation Biology, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, Melbourne, Australia.
Cancer Gene Ther. 2005 Oct;12(10):787-95. doi: 10.1038/sj.cgt.7700857.
RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous impact on experimental biology. RNA interference technologies are currently the most widely utilized techniques in functional genomic studies. Furthermore, there is an intense research effort aimed at developing short interfering RNAs for therapeutic purposes. A number of proof-of-principle experiments have demonstrated the clinical potential of appropriately designed short interfering RNAs in various diseases including viral infections, cancer and neurodegenerative disorders. Already, in such a short time from their discovery, Acuity Pharmaceuticals (August 2004) and Sirna Therapeutics (September 2004) have filed Investigational New Drug applications with the US FDA to begin clinical trials with modified siRNA molecules in patients with age-related macular degeneration. This review will give a brief overview of the mechanism of RNA interference and applications of the pathway in experimental biology will be discussed. The article will focus on recent developments related to the use of RNA interference technologies in mammalian systems and on potential clinical applications of short interfering RNA-mediated RNA interference.
RNA干扰是一种内源性基因沉默机制,涉及双链RNA介导的序列特异性mRNA降解。这一途径的发现以及对RNA干扰效应分子——小干扰RNA的结构和功能的阐明,对实验生物学产生了巨大影响。RNA干扰技术是目前功能基因组学研究中应用最广泛的技术。此外,人们正在进行大量研究工作,旨在开发用于治疗目的的小干扰RNA。一些原理验证实验已经证明,适当设计的小干扰RNA在包括病毒感染、癌症和神经退行性疾病在内的各种疾病中具有临床应用潜力。在它们被发现后的如此短的时间内,锐视制药公司(2004年8月)和Sirna治疗公司(2004年9月)已向美国食品药品监督管理局提交了研究性新药申请,以开始在年龄相关性黄斑变性患者中对修饰的siRNA分子进行临床试验。本综述将简要概述RNA干扰的机制,并讨论该途径在实验生物学中的应用。本文将重点关注与RNA干扰技术在哺乳动物系统中的应用相关的最新进展以及小干扰RNA介导的RNA干扰的潜在临床应用。